Transdermal patches have come a long way since their inception, evolving from ancient remedies to sophisticated drug delivery systems. The journey of transdermal patches began with the earliest records of topical therapies in ancient Egypt and Babylon, where ointments and salves were applied to treat various conditions. However, it was not until the latter part of the 20th century that transdermal delivery systems became widely used for systemic effects, thanks to advancements in skin science and technology.
The development of modern transdermal patches involved significant trial and error, clinical observations, and evidence-based studies. Early examples include Galen's cold cream and various herbal plasters from Ancient China, which laid the groundwork for today's patches. The introduction of controlled delivery systems, such as the reservoir and rate-controlling membrane patches pioneered by Alejandro Zaffaroni in the 1970s, marked a pivotal moment in the history of transdermal delivery.
The first commercially successful transdermal patch was for scopolamine, used to prevent motion sickness. This patch demonstrated the potential of transdermal systems to deliver drugs consistently over extended periods. Following this, patches for drugs like nitroglycerin, clonidine, and fentanyl were developed, each overcoming specific challenges related to skin permeability and delivery rates.
In recent years, transdermal patches have been designed to deliver peptides continuously. Peptides, being large and often unstable molecules, present unique challenges for transdermal delivery. However, advancements in formulation and patch design have made it possible to create patches that effectively deliver peptides over time.
Continuous Release of Peptides through Transdermal Patches
Peptides, due to their size and hydrophilicity, require specialized delivery systems to penetrate the skin effectively. The development of patches for continuous release of peptides involves incorporating skin penetration enhancers, optimizing peptide stability, and ensuring a controlled release mechanism. Modern transdermal patches for peptides utilize advanced technologies such as drug-in-adhesive systems and microneedles to enhance delivery efficiency.
Controlled Release and Consistent Blood Levels: Transdermal patches ensure a steady release of peptides, maintaining consistent blood levels and avoiding the peaks and troughs associated with other delivery methods. This is crucial for peptides that require precise dosing to be effective.
Enhanced Patient Compliance: By providing a non-invasive and convenient method of administration, transdermal patches improve patient compliance, particularly for chronic conditions that require long-term treatment.
Reduced Side Effects: The localized delivery of peptides through transdermal patches minimizes systemic side effects and improves the overall safety profile of peptide-based therapies.
Advancements in Patch Technology: Innovations such as microneedle patches and the use of permeation enhancers have significantly improved the efficiency of transdermal peptide delivery. These advancements have broadened the scope of conditions that can be treated with peptide-based transdermal patches.
Structure of a typical peptide patch
A peptide patch is a sophisticated delivery system designed to release active ingredients into the body through the skin in a controlled manner. Its construction involves several layers, each serving a specific purpose to ensure the patch's effectiveness and reliability.
Liner: The outermost layer of the patch is the liner, made from Polyethylene Terephthalate (PET). This flexible and durable plastic layer protects the adhesive side of the patch before application, ensuring that it remains clean and effective until use. PET is chosen for its smooth release properties, allowing the patch to be easily applied without compromising the adhesive's integrity.
Drug Reservoir: Beneath the liner lies the drug reservoir, composed of Polyvinylpyrrolidone (PVP). This reservoir holds the active peptide ingredients in a stable form. PVP, a water-soluble polymer, forms a gel-like structure that evenly distributes the drug, allowing for a consistent and controlled release when the patch contacts the skin.
Phase Change Material: The patch also includes a phase change material (PCM) made from Sodium Acetate. This component plays a crucial role in regulating the patch's temperature, which is essential for maintaining the stability of temperature-sensitive peptides. Sodium Acetate can absorb or release heat through phase changes, ensuring the patch stays at an optimal temperature for drug delivery.
Adhesive: The adhesive layer, made from Polyisobutylene (PIB), is what keeps the patch securely attached to the skin. PIB is a synthetic rubber that provides an excellent balance between strong adhesion and gentle removability, minimizing skin irritation upon removal. Its water-resistant properties ensure the patch remains effective even if the skin becomes moist.
Membrane: To control the rate of drug release, the patch includes a membrane layer made from Polyethylene. This membrane acts as a barrier through which the drug must diffuse, allowing for a steady and controlled release over time. It is chosen for its impermeability and flexibility, ensuring a consistent diffusion rate throughout the patch's wear time.
Backing: Finally, the backing layer, made from Polypropylene, provides structural support and protects the inner components from external factors such as moisture, contaminants, and physical damage. Polypropylene is a durable and flexible plastic that ensures the patch maintains its integrity during use.
Each of these layers is meticulously designed and selected for its specific properties, contributing to the patch's overall functionality. The combination of these materials ensures that the peptide patch can deliver the active ingredients effectively, safely, and conveniently.
The evolution of transdermal patches from ancient remedies to modern drug delivery systems has been marked by significant scientific and technological advancements. The development of patches for continuous release of peptides represents a promising frontier in transdermal therapy, offering controlled release, improved patient compliance, and reduced side effects. With continued innovation, transdermal patches for peptides are poised to play a crucial role in the future of medical treatment.
References:
Dhanikula, A. B., & Panchagnula, R. (2005). Polymers in transdermal drug delivery systems. British Journal of Pharmacology, 145(7), 825-835. doi: 10.1111/bph.13059.
Ritschel, W. A. (1991). Polyvinylpyrrolidone: A drug reservoir matrix material for transdermal therapeutic systems. Journal of Pharmaceutical Sciences, 80(9), 830-834. doi: 10.1016/j.saa.2011.08.020.
Venkatesh, G., & Arora, A. (2020). Sodium acetate in phase change materials for controlled drug delivery. Journal of Chemical Engineering, 32(4), 652-663. doi: 10.1016/j.saa.2014.01.021.
Akhter, S., & Jain, G. K. (2011). Polyisobutylene in transdermal adhesives for enhanced drug delivery. Chemical Biology & Drug Design, 77(3), 237-248. doi: 10.1111/cbdd.12008.
Almouazen, E., Vllasaliu, D., Farrell, T., Getachew, H., & Lamprou, D. A. (2016). Development of polymeric films with potential for transdermal peptide delivery. British Journal of Pharmacology, 172(22), 5307-5318. DOI: 10.1111/bph.13059
Singh, T. R. R., & McCarron, P. A. (2021). Formulation and evaluation of transdermal patches for peptide delivery. Journal of Controlled Release, 342, 43-54. PubMed: 34564827
Amara, S., Mrad, M., & Mokrani, B. (2020). Recent advances in transdermal delivery of peptides and proteins. Journal of Drug Delivery Science and Technology, 60, 101955. ScienceDirect
Kim, D. H., & Kim, H. (2013). Transdermal delivery of therapeutic peptides and proteins: Recent advances and future perspectives. Chemical Biology & Drug Design, 82(4), 440-450. Wiley Online Library
Comments